Hikma forecasts 2020 growth after its profit tops as treatment demand grows

(Reuters) - Hikma Pharmaceuticals on Thursday forecast sales growth for 2020 after it surpassed analysts' expectations for annual operating profit and revenue, as demand for its injectable treatments and newly launched drugs in the United States rose.The company, which makes and markets a broad range of branded and non-branded generic medicines, said core operating profit rose 10% to $508 million (393 million pounds) for the year ended Dec. 31. Analysts on average were expecting core profit..